Skip to main content

Table 2 In vitro cytotoxicity effect (IC50) of Caelyx, A6-PLD, and free doxorubicin against C-26 and NIH-3T3 cells after different exposure times

From: CD44-specific short peptide A6 boosts cellular uptake and anticancer efficacy of PEGylated liposomal doxorubicin in vitro and in vivo

Treatment

C-26 cells (3 h)

C-26 cells (6 h)

NIH-3T3 cells (3 h)

NIH-3T3 cells (6 h)

Free dox

0.34 ± 0.08

0.25 ± 0.09

4.33 ± 0.24

3. 73 ± 0.44

PLD

15.98 ± 2.35

15.02 ± 3.05

41. 35 ± 8.65

38.05 ± 6.68

A6- PLD

9.34 ± 1.54

7.52 ± 2.05

39.32 ± 9.15

34.87 ± 4.68

  1. Data represented as μg/ml ± standard deviation (n = 3)
Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us